You Position: Home > Paper
Efficacy of gefitinib in the treatment of locally advanced or metastatic non-small cell lung cancer
( views:1, downloads:0 )
- Author:
- No author available
- Journal Title:
- CHINESE JOURNAL OF NEW DRUGS
- Issue:
- 10
- DOI:
- No doi available
- Key Word:
- 吉非替尼;非小细胞肺癌;靶向治疗
Abstract： 目的:分析吉非替尼治疗局部晚期或转移性非小细胞肺癌(NSCLC)的疗效、中位生存期、无进展生存期及对症状的控制,同时分析与疗效和生存期可能相关的因素.方法:46例局部晚期或转移性NSCLC口服吉非替尼250 mg·d-1,直至出现肿瘤进展或不可耐受的毒副反应.服药前及服药后每4周进行肿瘤和全身评估.结果:46例可评价病例中,无完全缓解(CR),部分缓解(PR)14例,病情稳定(SD)20例,疾病进展(PD)12例.全组缓解率ORR为30.4%,疾病控制率DCR为73.9%.疾病相关症状缓解率为71.7%,中位症状缓解时间为8 d.症状改善持续中位时间为6.2个月;中位疾病进展时间6个月.中位生存期10.2个月,女性、腺癌、肺内病灶小或肺内弥漫病灶、有皮疹和腹泻的患者疾病控制率高,近期疗效好.主要不良反应为皮疹、腹泻.结论:吉非替尼治疗局部晚期和转移性非小细胞肺癌有较好近期疗效和生存益处.
- [1]吴一龙,杨衿记,林嘉颖,等.吉非替尼靶向治疗非小细胞肺癌的临床研究[J].2007,(2).
- [2]陆舜,李子明.肺癌靶向治疗--来自亚洲的数据[J].2007,(1).
- [3]D M, Parkin,F I, Bray,S S, Devesa.Cancer burden in the year 2000. The global picture.[J].2001,37 Suppl 8.
- [4]Averbuch S,Horai T,Nakagawa K,etc.Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer.[J].2003,21(12).
- [5]Paul A, Bunn.Treatment of advanced non-small-cell lung cancer with two-drug combinations.[J].2002,20(17).